| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
|
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
 |
Use in accordance with local guidelines
|
|
Abemaciclib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
 NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (CDF)
|
Alectinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
|
Arsenic trioxide injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
Approved as per licensed dosing, or dosing in the AML17 trial protocol (off-label). Refer to local guidelines and treatment protocols.
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
Atezolizumab injection (breast cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
|
Atezolizumab injection (hepatocellular cancer indications)
|
Formulary
|
 Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
|
Atezolizumab injection (lung cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
|
Atezolizumab injection (urothelial cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF)
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
|
Avelumab injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below)
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma (CDF)
|
Avelumab injection (renal cell carcinoma)
|
Formulary
|
 Approved for use as per NICE technology appraisal guidance (see links below)
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Axicabtagene ciloleucel cells dispersion for infusion
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.
Refer to SPC for information on management of cytokine release syndrome.
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF)
|
Axitinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma (CDF)
|
Binimetinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Bosutinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brentuximab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
Brigatinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Carfilzomib injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Aug 2019: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
MHRA Nov 2019: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
NICE TA657: Carfilzomib for previously treated multiple myeloma
|
Cemiplimab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CDF)
|
Ceritinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Dacomitinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Durvalumab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF)
|
Encorafenib caps (colorectal)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
|
Encorafenib caps (melanoma)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Entrectinib caps
|
Formulary
|
Approved for use as per NICE Technology appraisal guidance (see links below)
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
|
Entrectinib caps (non-small cell lung cancer)
|
Formulary
|
Approved for use as per NICE Technology appraisal guidance (see links below)
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Eribulin injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Gilteritinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Ibrutinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (CDF)
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Idelalisib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
|
Inotuzumab ozogamicin injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Isatuximab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see link below)
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
|
Ketoconazole tabs
|
 Restricted
|
Approved off-label indication:
Management of castration refractory prostate cancer
Dose = 200-400mg three times daily
|
|
|
Larotrectinib oral solution
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see link below)
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
|
Lutetium (177Lu) oxodotreotide injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
|
Midostaurin caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia
|
Neratinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
|
Niraparib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Oct 20: Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (CDF)
|
Nivolumab injection (haematological and lung cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (CDF)
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
|
Nivolumab injection (head and neck, renal and skin cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF)
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF)
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF)
|
Nivolumab injection (urothelial cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
|
Olaparib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below)
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (CDF)
|
Palbociclib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF)
|
Panitumumab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Panobinostat caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pegaspargase injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
|
Pembrolizumab injection (lymphoma and lung cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (CDF)
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (CDF)
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF)
|
Pembrolizumab injection (skin cancer and head and neck cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF)
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Pembrolizumab injection (urothelial cancer indications)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (CDF)
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF)
|
Pertuzumab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Polatuzumab vedotin injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Ponatinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Apr 2017: Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
MHRA Oct 2018: Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Regorafenib tabs (gastrointestinal stromal tumours)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
|
Regorafenib tabs (hepatocellular carcinoma)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Ribociclib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF)
|
Rucaparib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (CDF)
|
Ruxolitinib tabs (licensed use)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Ruxolitinib tabs (use in graft vs host disease - off-label)
|
Formulary
|
Approved off-label indication:
Acute and chronic graft vs host disease as per criteria listed in NHSE policies (see links below)
|
 NHSE Rapid policy statement: Ruxolitinib for acute graft versus host disease (RPS 2009)
NHSE Rapid policy statement: Ruxolitinib for chronic graft versus host disease (RPS 2010)
|
Talimogene laherparepvec injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Tisagenlecleucel cells dispersion for infusion
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.
Refer to SPC for information on management of cytokine release syndrome.
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (CDF)
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (CDF)
|
Trametinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Venetoclax tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (CDF)
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (CDF)
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (CDF)
|
Streptozocin injection
|
 Unlicensed
|
Locally advanced and metastatic neuroendocrine tumours (predominantly pancreas but also small/large bowel and lung)
For named supervising consultants only in accordance with the prescribing protocol and proforma
|
|
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine injection
|
Formulary
|
|
|
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab injection (licensed use)
|
Formulary
|
Approved as per indications in the Cancer Drugs Fund
|
|
|
Bevacizumab injection (neurofibromatosis type 2 - off-label)
|
Formulary
|
Approved off-label indication:
Treatment of neurofibromatosis type 2
For consultant specialists in accordance with a nationally commissioned service protocol
|
|
|
| 08.01.05 |
Bexarotene |
|
|
Bexarotene caps
|
Formulary
|
Use in accordance with LCNDG guidance
|
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (CDF)
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab injection (colorectal cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Feb 2014: Cetuximab: Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
|
Cetuximab injection (head and neck cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Crisantaspase |
|
|
Crisantaspase injection
|
Formulary
|
|
|
|
Asparaginase injection
|
Unlicensed
|
Acute lymphoid leukaemia
|
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine injection
|
Formulary
|
|
|
|
Temozolomide caps (licensed use)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
Temozolomide caps (pancreatic neuroendocrine tumours - off-label)
|
Restricted
|
Approved off-label indication:
Unresectable or metastatic pancreatic neuroendocrine tumours (in combination with capecitabine). Follow local protocol for use.
|
|
|
Temozolomide caps (pituitary adenomas - off-label)
|
Restricted
|
Approved off-label indication:
Treatment of pituitary adenomas refractory to surgery and radiotherapy
Initiation restricted to Consultant Endocrinologists who are part of the Trust MDM, in accordance with a treatment protocol at KCH
|
|
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide caps, tabs, oral solution
|
Formulary
|
Cancer indications
 Non-cancer licensed indications
|
|
|
| 08.01.05 |
Imatinab |
|
|
Imatinib tabs (licensed commissioned use)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
Also approved for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) (NHSE commissioned)
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
|
Imatinib tabs (Graft vs Host Disease - off-label)
|
Formulary
|
Approved off-label indication:
Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy (see link below)
|
NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Jan 2019: Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF)
|
| 08.01.05 |
Mitotane |
|
|
Mitotane tabs
|
Restricted
|
Treatment of patients with:
- Biochemical or radiological evidence of persistent or relapsed adrenocortical carcinoma
- Apparent complete resection of adrenocortical carcinoma for adjuvant therapy
|
|
|
| 08.01.05 |
Pentostatin |
|
|
Pentostatin injection (Graft vs Host Disease - off-label)
|
Formulary
|
Approved off-label indication:
Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy (see link below)
|
NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
|
Pentostatin injection (licensed use)
|
Formulary
|
|
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin injection
|
Formulary
|
|
|
|
Cisplatin injection
|
Formulary
|
|
|
|
Oxaliplatin injection
|
Formulary
|
|
NICE CG131: Colorectal cancer: diagnosis and management
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine caps
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Cabozantinib caps (Cometriq - thyroid cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer
|
Cabozantinib tablets (Cabometyx - renal carcinoma)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (CDF)
|
Dasatinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Everolimus tabs (breast cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
|
Everolimus tabs (neuroendocrine tumours)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Everolimus tabs (renal cancer)
|
Formulary
|
Approved as per NICE TA guidance (see links below)
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus tabs (seizures associated with tuberous sclerosis complex)
|
Formulary
|
Approved for use in refractory seizures associated with tuberous sclerosis complex as per NHS England Polcy (see link below)
|
NHSE Clinical Commissioning Policy 170093P: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex
|
Gefitinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
|
Lenvatinib caps (hepatocellular carcinoma - Lenvima®)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Lenvatinib caps (renal cancer - Kisplyx®)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Lenvatinib caps (thyroid cancer - Lenvima®)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Lorlatinib tabs (Non-small-cell lung cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
|
Nilotinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nintedanib caps (Vargatef® Non-small-cell lung cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
|
Osimertinib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA653: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Pazopanib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
|
Sorafenib tablets (Hepatocellular carcinoma)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
|
Sorafenib tablets (thyroid cancer)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib caps (gastrointestinal stromal tumours and neuroendocrine tumours)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Sunitinib caps (renal cell carcinoma)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
|
Tivozanib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib tabs
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel injection
|
Formulary
|
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
|
Paclitaxel albumin injection (Abraxane)
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
Paclitaxel injection
|
Formulary
|
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride injection
|
Formulary
|
|
NICE CG131: Colorectal cancer: diagnosis and management
|
Topotecan injection
|
Formulary
|
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
|
Irinotecan hydrochloride (for liver metastases - locoregional delivery via drug eluting beads)
|
Unlicensed
|
For locoregional treatment of liver metastases in colorectal cancer
100 mg given via drug-eluting beads (DC Bead™ or DC Bead M1™ - Boston Scientific)
|
|
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
|
| 08.01.05 |
Trastuzumab |
|
|
Trastuzumab emtansine injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
|
Trastuzumab injection
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below)
Biosimilar products available, to be prescribed by brand name.
Contact pharmacy department for advice on brand for routine prescribing if unsure
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin caps
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Eribulin injection
|
Non Formulary
|
Not approved for use in SE London for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen as per NICE Technology appraisal guidance (see link below) |
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
|
Idelalisib tabs
|
Non Formulary
|
Not approved for use in SE Lonndon for refractory follicular lymphoma as per NICE Technology appraisal guidance (see links below): |
NICE TA604: Idelalisib for treating refractory follicular lymphoma
|
Necitumumab injection
|
Non Formulary
|
Not approved for use in SE London for untreated advanced or metastatic squamous non-small-cell lung cancer as per NICE Technology appraisal guidance (see link below) |
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
|
Pegylated liposomal irinotecan injection
|
Non Formulary
|
Not approved for use in SE London for treating pancreatic cancer as per NICE Technology appraisal guidance (see link below) |
MHRA Mar 19: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
|
Pembrolizumab injection
|
Non Formulary
|
Not approved for use in SE London with axitinib for untreated advanced renal cell carcinoma as per NICE Technology Appraisal guidance (see link below) |
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
|
Vandetanib tabs
|
Non Formulary
|
Not approved for use in SE London for treating medullary thyroid cancer as per NICE Technology appraisal guidance (see link below) |
NICE TA550: Vandetanib for treating medullary thyroid cancer
|
Vismodegib caps
|
Non Formulary
|
Not approved for use in SE London for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapyas per NICE Technology appraisal guidance (see link below) |
NICE TA489: Vismodegib for treating basal cell carcinoma
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|
|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |
|
Specialist initiation followed by maintenance prescribing in primary care |
|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |
|
Specialist and non-specialist initiation |
|
Not recommended for prescribing |
|
|
|
